Gotham Asset Management LLC Has $10.54 Million Stock Holdings in Hologic, Inc. $HOLX

Key Points

• Gotham Asset Management LLC has significantly reduced its position in Hologic, Inc. by 49.4%, selling 166,661 shares and retaining 170,608 shares valued at approximately $10.5 million.
• Various institutional investors have altered their stakes in Hologic, with 94.73% of the stock now owned by institutional investors and hedge funds.
• Hologic's latest earnings report revealed an EPS of $1.08, surpassing analysts' expectations, and the company has set a Q4 2025 EPS guidance between 1.090 and 1.120.

Gotham Asset Management LLC reduced its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 49.4% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 170,608 shares of the medical equipment provider's stock after selling 166,661 shares during the period. Gotham Asset Management LLC owned about 0.08% of Hologic worth $10,538,000 at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of the stock. Victory Capital Management Inc. grew its stake in shares of Hologic by 34.4% during the 1st quarter. Victory Capital Management Inc. now owns 6,609,728 shares of the medical equipment provider's stock valued at $408,283,000 after acquiring an additional 1,692,177 shares during the period. Nuance Investments LLC raised its stake in shares of Hologic by 623.7% in the first quarter. Nuance Investments LLC now owns 1,081,333 shares of the medical equipment provider's stock worth $66,794,000 after purchasing an additional 931,920 shares during the last quarter. Redwood Wealth Management Group LLC acquired a new stake in Hologic in the first quarter valued at approximately $3,534,000. Invesco Ltd. boosted its stake in shares of Hologic by 18.8% in the first quarter. Invesco Ltd. now owns 4,834,957 shares of the medical equipment provider's stock worth $298,655,000 after acquiring an additional 764,573 shares during the last quarter. Finally, Nuveen LLC purchased a new stake in Hologic in the first quarter valued at $30,317,000. Hedge funds and other institutional investors own 94.73% of the company's stock.

Hologic Stock Performance

Shares of HOLX traded up $0.18 on Tuesday, reaching $66.72. The company's stock had a trading volume of 1,186,914 shares, compared to its average volume of 1,570,787. The stock has a market capitalization of $14.84 billion, a P/E ratio of 27.68, a PEG ratio of 2.42 and a beta of 0.57. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.55 and a quick ratio of 2.81. Hologic, Inc. has a 12-month low of $51.90 and a 12-month high of $84.39. The stock's 50 day simple moving average is $66.40 and its two-hundred day simple moving average is $62.63.

Hologic (NASDAQ:HOLX - Get Free Report) last announced its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a net margin of 13.79% and a return on equity of 19.69%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the company posted $1.06 earnings per share. The firm's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. Research analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have weighed in on HOLX. Argus raised Hologic from a "hold" rating to a "buy" rating and set a $80.00 price objective for the company in a research report on Monday, August 18th. Royal Bank Of Canada raised Hologic from a "sector perform" rating to an "outperform" rating and boosted their target price for the stock from $72.00 to $87.00 in a report on Wednesday, August 6th. Needham & Company LLC restated a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Mizuho set a $75.00 price target on shares of Hologic in a research note on Thursday, July 31st. Finally, Morgan Stanley lifted their price target on shares of Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a research note on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $78.00.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.